The Manufacturers Life Insurance Company Makes New $517,000 Investment in Artivion, Inc. $AORT

The Manufacturers Life Insurance Company purchased a new position in shares of Artivion, Inc. (NYSE:AORT) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 23,002 shares of the company’s stock, valued at approximately $517,000.

A number of other large investors have also made changes to their positions in the stock. Royal Bank of Canada grew its position in Artivion by 107.0% during the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after buying an additional 20,010 shares during the period. AQR Capital Management LLC increased its holdings in Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after acquiring an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Artivion by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after purchasing an additional 1,032 shares in the last quarter. Creative Planning grew its position in shares of Artivion by 5.6% in the second quarter. Creative Planning now owns 14,272 shares of the company’s stock valued at $444,000 after purchasing an additional 753 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after purchasing an additional 139,370 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on AORT. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Citigroup reissued a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Artivion in a research note on Monday, July 20th. Canaccord Genuity Group boosted their price objective on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Finally, Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research note on Monday, June 1st. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Insider Buying and Selling

In other Artivion news, SVP Jean Holloway sold 977 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares in the company, valued at $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Andrew Green sold 1,493 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.02, for a total transaction of $38,847.86. Following the completion of the transaction, the senior vice president directly owned 51,640 shares in the company, valued at approximately $1,343,672.80. This represents a 2.81% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 122,981 shares of company stock valued at $3,181,531. 6.30% of the stock is currently owned by corporate insiders.

Artivion Stock Up 0.1%

Shares of AORT opened at $25.59 on Monday. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The company’s fifty day moving average is $26.09 and its two-hundred day moving average is $29.16. The firm has a market cap of $1.25 billion, a PE ratio of -365.52 and a beta of 1.25. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The firm had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current year.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.